Baird raised the firm’s price target on Edwards Lifesciences (EW) to $79 from $78 and keeps a Neutral rating on the shares. The firm updated its model following strong Q2 results and the beat raises confidence in the second half 2025 TAVR acceleration.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EW:
- Edwards Lifesciences price target raised to $89 from $85 at RBC Capital
- Edwards Lifesciences price target raised to $81 from $75 at Canaccord
- Edwards Lifesciences price target raised to $94 from $85 at Deutsche Bank
- Edwards Lifesciences price target raised to $85 from $80 at JPMorgan
- Edwards Lifesciences: Strong Financial Performance and Strategic Advancements Drive Buy Rating